Human studies in the development of human immunodeficiency virus vaccines
- PMID: 7594651
- DOI: 10.1093/infdis/172.5.1175
Human studies in the development of human immunodeficiency virus vaccines
Abstract
The safety and immunogenicity of candidate human immunodeficiency virus type 1 (HIV-1) vaccines have been studied in > 1500 healthy, seronegative (HIV-1-uninfected) subjects. HIV-1 envelope proteins, gp160 and gp120, have been the most extensively investigated. A live virus vector construct, vaccinia with insertion of the HIV-1 env gene, has also been studied. HIV-1 candidate vaccines have been well tolerated, with no acute or longer-term serious toxicity. Intramuscular multidose gp120 vaccines induce neutralizing antibodies, lymphoproliferative responses, and anti-HIV-1 CD4 cytotoxic T cell (CTL) activity. Immunization with the vaccinia-env construct, followed by a boost with an envelope protein, also induces neutralizing antibodies, and anti-HIV-1 CTL activity (CD8, major histocompatibility complex class I-restricted) has been observed. To date, serum from vaccinees can neutralize laboratory-adapted HIV-1 strains in vitro but not primary isolates; the significance of this observation is unknown. Additional approaches to vaccination against HIV-1 are in development.
Similar articles
-
Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2443-7. doi: 10.1073/pnas.90.6.2443. Proc Natl Acad Sci U S A. 1993. PMID: 8460155 Free PMC article. Clinical Trial.
-
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.J Infect Dis. 1993 Mar;167(3):533-7. doi: 10.1093/infdis/167.3.533. J Infect Dis. 1993. PMID: 8095059 Clinical Trial.
-
HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.Virus Genes. 1994 Jul;8(3):249-70. doi: 10.1007/BF01704519. Virus Genes. 1994. PMID: 7975271 Review.
-
Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.J Virol. 1994 May;68(5):3145-53. doi: 10.1128/JVI.68.5.3145-3153.1994. J Virol. 1994. PMID: 7908700 Free PMC article.
-
How antibodies block HIV infection: paths to an AIDS vaccine.Trends Biochem Sci. 1992 May;17(5):191-6. doi: 10.1016/0968-0004(92)90265-b. Trends Biochem Sci. 1992. PMID: 1350693 Review.
Cited by
-
Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.J Virol. 2006 Jun;80(11):5552-62. doi: 10.1128/JVI.02094-05. J Virol. 2006. PMID: 16699036 Free PMC article.
-
Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases.Ann Surg. 1999 Sep;230(3):352-60; discussion 360-1. doi: 10.1097/00000658-199909000-00008. Ann Surg. 1999. PMID: 10493482 Free PMC article.
-
Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.J Virol. 1999 Oct;73(10):8201-15. doi: 10.1128/JVI.73.10.8201-8215.1999. J Virol. 1999. PMID: 10482571 Free PMC article.
-
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.J Virol. 1998 Nov;72(11):9092-100. doi: 10.1128/JVI.72.11.9092-9100.1998. J Virol. 1998. PMID: 9765454 Free PMC article.
-
A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1.J Virol. 1998 Jul;72(7):5680-98. doi: 10.1128/JVI.72.7.5680-5698.1998. J Virol. 1998. PMID: 9621027 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
